European sales of Humira are already sinking in response to biosimilar competition, and AbbVie offset a lot of that loss by raising the list price in the U.S. 19.1% during the time frame studied. AbbVie: Humira AbbVie's flagship anti-inflammation injection, Humira, has proven itself useful many times over since launching in 2002 -- but not during the two-year period between the end of 2016 and 2018. If AbbVie had simply raised Humira's price in line with the medical care consumer price index (CPI), though, it would have risen around $427 million.